Literature DB >> 15692475

Placebo-controlled oral pulse prednisolone therapy in alopecia areata.

Bikash Ranjan Kar1, Sanjeev Handa, Sunil Dogra, Bhushan Kumar.   

Abstract

BACKGROUND: Systemic corticosteroids administered as pulse therapy have been found helpful in a wide array of diseases including alopecia areata (AA). None of the studies published so far regarding their use in AA have been randomized or placebo-controlled.
OBJECTIVE: We sought to compare the efficacy of weekly oral prednisolone pulse therapy in a placebo-controlled trial for patients with extensive AA.
METHODS: A total of 43 patients were randomly divided into two groups. Patients in group A (23 patients) were treated with oral prednisolone (200 mg once weekly, 5 40-mg tablets) and patients in group B (20 patients) were given placebo tablets on an identical schedule. The total study period was 6 months, consisting of 3 months of active therapy followed by another 3 months of observation.
RESULTS: Significant hair regrowth was obtained in 8 patients in the prednisolone-treated group. Two of the responders experienced a relapse during the observation period of 3 months. In the placebo group, none of the patients had significant hair regrowth at the end of the study.
CONCLUSION: Oral prednisolone pulse therapy is useful in AA. Placebo-controlled studies with varying dosage schedules are required to standardize the dose of prednisolone used in pulse therapy, optimize the therapeutic efficacy, and minimize side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15692475     DOI: 10.1016/j.jaad.2004.10.873

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  23 in total

Review 1.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Medium-dose prednisolone pulse therapy in alopecia areata.

Authors:  Pinelopi Efentaki; Andreas Altenburg; Johannes Haerting; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-11

Review 3.  Alopecia areata: Part 2: treatment.

Authors:  Frank Spano; Jeff C Donovan
Journal:  Can Fam Physician       Date:  2015-09       Impact factor: 3.275

4.  Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids.

Authors:  Deborah Lee; Doo Jin Oh; Jung Wook Kim; Sung Wook Park; Min Kyung Oh; Ho Suk Sung; Seon Wook Hwang
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

Review 5.  Alopecia Areata: An Update on Treatment Options for Children.

Authors:  Lauren Peloquin; Leslie Castelo-Soccio
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

Review 6.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

7.  A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices.

Authors:  Christina Stefanaki; George Kontochristopoulos; Eleni Hatzidimitraki; Aravella Stergiopoulou; Alexandra Katsarou; Vasiliki Vosynioti; Eleni Remountaki; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2021-09-14

Review 8.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

9.  Corticosteroids for alopecia areata in children.

Authors:  Tharindu Fernando; Ran D Goldman
Journal:  Can Fam Physician       Date:  2020-07       Impact factor: 3.275

10.  Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: a retrospective study with a self-controlled design.

Authors:  Kui Young Park; Woo Sun Jang; In Pyeong Son; Sun Young Choi; Moo Yeol Lee; Beom Joon Kim; Myeung Nam Kim; Byung In Ro
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.